Stephen Hale

FAQ About Stephen Hale

• What is Stephen Hale's address?

  Stephen Hale is located at
  Cambridge, Massachusetts, United States

• What is Stephen Hale's job title?

  Stephen Hale is a
  Steve has over 25 years of drug discovery experience, most recently as: -CEO and Founder of DG Medicines -An operational founder and Global Head of Discovery at Dewpoint Therapeutics -A founder of 2 autoimmune-focused therapeutics companies; A founding member of an E3 Ligase-targeting company in the oncology and neuro-degeneration therapeutic areas. -A consultant and entrepreneur advising over 30 emerging and established companies Prior to consulting and venture creation, Steve was CSO of Ensemble Therapeutics where he built a drug discovery platform supporting 6 major collaborations that raised over 100M in non-dilutive capital. At Ensemble he was responsible for initiating and advancing internal and partnered programs that leveraged DNA-encoded macrocyclic compound collections and a massively parallel screening process. Programs were advanced in oncology, immune modulation, cardiovascular, neurodegeneration, and anti-infectives with an IL17, and IDO antagonists of novel mechanism being acquired and advanced towards the clinic. Before joining Ensemble, Steve was at Praecis Pharmaceuticals where he was co-inventor of a transformative DNA-Encoded Library (DEL) and screening technology that has since become ubiquitous in the industry as the gold-standard for encoded-small-molecule discovery. Programs in oncology were advanced including the approval of Plenaxis for prostate cancer prior to an acquisition by GSK. He joined Praecis from Phylos (Adnexus/BMS), a therapeutics discovery and development company where he was a founding scientist and led the anti-VEGFR2 program (BMS844203) that progressed to phase 2. Dr. Hale was also involved in early work at Genex Inc. on the design and engineering of single-chain antibodies. He received his Ph.D. in biochemistry/chemistry from the University of Maryland, College Park, under Professor John Gerlt and was a National Institutes of Health post-doctoral fellow at the Massachusetts Institute of Technology under the direction of Professor Paul Schimmel. Stablix

• What industry does Stephen Hale currently work in?

  Stephen Hale currently works in the
  Stablix

• What is Stephen Hale's area of expertise?

  Stephen Hale specializes in
  Steve has over 25 years of drug discovery experience, most recently as: -CEO and Founder of DG Medicines -An operational founder and Global Head of Discovery at Dewpoint Therapeutics -A founder of 2 autoimmune-focused therapeutics companies; A founding member of an E3 Ligase-targeting company in the oncology and neuro-degeneration therapeutic areas. -A consultant and entrepreneur advising over 30 emerging and established companies Prior to consulting and venture creation, Steve was CSO of Ensemble Therapeutics where he built a drug discovery platform supporting 6 major collaborations that raised over 100M in non-dilutive capital. At Ensemble he was responsible for initiating and advancing internal and partnered programs that leveraged DNA-encoded macrocyclic compound collections and a massively parallel screening process. Programs were advanced in oncology, immune modulation, cardiovascular, neurodegeneration, and anti-infectives with an IL17, and IDO antagonists of novel mechanism being acquired and advanced towards the clinic. Before joining Ensemble, Steve was at Praecis Pharmaceuticals where he was co-inventor of a transformative DNA-Encoded Library (DEL) and screening technology that has since become ubiquitous in the industry as the gold-standard for encoded-small-molecule discovery. Programs in oncology were advanced including the approval of Plenaxis for prostate cancer prior to an acquisition by GSK. He joined Praecis from Phylos (Adnexus/BMS), a therapeutics discovery and development company where he was a founding scientist and led the anti-VEGFR2 program (BMS844203) that progressed to phase 2. Dr. Hale was also involved in early work at Genex Inc. on the design and engineering of single-chain antibodies. He received his Ph.D. in biochemistry/chemistry from the University of Maryland, College Park, under Professor John Gerlt and was a National Institutes of Health post-doctoral fellow at the Massachusetts Institute of Technology under the direction of Professor Paul Schimmel.

• Which languages does Stephen Hale speak? 

  Stephen Hale speaks the following languages:
  No languages available.

• Which industries has Stephen Hale previously worked in?   

  Stephen Hale has prior experience in the following industries:
  Dewpoint Therapeutics , Ensemble Therapeutics , Ensemble Therapeutics , Ensemble Therapeutics , Ensemble Therapeutics , Praecis , Praecis , Praecis , Phylos , Phylos , Phylos , Phylos , Massachusetts Institute Of Technology , Genex , Eks Center Harvard Medical School , Normandeau Associates

• What is Stephen Hale’s work experience?  

  Stephen Hale has the following professional experience:
  Stablix , Totus Medicines , Dg Medicines , Dewpoint Therapeutics , Biotech Pharma And Venture Capital , Ensemble Therapeutics , Ensemble Therapeutics , Ensemble Therapeutics , Ensemble Therapeutics , Praecis , Praecis , Praecis , Phylos , Phylos , Phylos , Phylos , Massachusetts Institute Of Technology , Genex , Eks Center Harvard Medical School , Normandeau Associates .

• How can I find Stephen Hale on LinkedIn?  

  You can view Stephen Hale’s
  LinkedIn profile at LinkedIn URL.

• What are Stephen Hale’s work email addresses?  

  Stephen Hale’s work email addresses are
  [email protected] .

• What company does Stephen Hale work for?  

  Stephen Hale works at
  Stablix